Masimo Free Cash Flow 2010-2024 | MASI

Masimo free cash flow for the twelve months ending June 30, 2024 was , a year-over-year.

  • Masimo annual free cash flow for 2023 was $0.05B, a 314.1% decline from 2022.
  • Masimo annual free cash flow for 2022 was $-0.023B, a 109.79% decline from 2021.
  • Masimo annual free cash flow for 2021 was $0.239B, a 72.51% increase from 2020.

Masimo Free Cash Flow 2010-2024 | MASI

  • Masimo annual free cash flow for 2023 was $0.05B, a 314.1% decline from 2022.
  • Masimo annual free cash flow for 2022 was $-0.023B, a 109.79% decline from 2021.
  • Masimo annual free cash flow for 2021 was $0.239B, a 72.51% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$211B
Intuitive Surgical (ISRG)$191.1B
Alcon (ALC)$45.7B
IQVIA Holdings (IQV)$39.8B
Edwards Lifesciences (EW)$39.1B
IDEXX Laboratories (IDXX)$35.5B
DexCom (DXCM)$27.3B
Waters (WAT)$22.8B
SONOVA HOLDING (SONVY)$22.1B
STERIS (STE)$21.6B
Hologic (HOLX)$18.3B
Sysmex ADR (SSMXY)$12.9B
Fresenius Medical Care AG KGaA (FMS)$12.5B
Globus Medical (GMED)$11B
Teleflex (TFX)$9.1B
Penumbra (PEN)$9.1B
Glaukos (GKOS)$7.8B
PROCEPT BioRobotics (PRCT)$5.2B
Integer Holdings (ITGR)$4.6B
Inari Medical (NARI)$3B
TransMedics (TMDX)$2.9B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.8B
Nihon Kohden (NHNKY)$2.6B
Elekta AB (EKTAY)$2.3B
Tandem Diabetes Care (TNDM)$2B
Integra LifeSciences Holdings (IART)$1.9B
RxSight (RXST)$1.8B
Alphatec Holdings (ATEC)$1.3B
Pulse Biosciences (PLSE)$1.2B